ClinicalTrials.gg
CompletedNCT00291655Updated May 18, 2015Results posted

Follow up Trial for Keppra (Levetiracetam) as Monotherapy in Patients With Newly Diagnosed Epilepsy Coming From N01175 (NCT00175903).

A Phase 3 interventional study of Levetiracetam in Epilepsy, sponsored by UCB Pharma. Completed at 35 sites in 6 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2015-05-18.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
130
Allocation
Non-randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing levetiracetam in Epilepsy — 4 open to participants now, 4 under way, 2 of them phase 3. Levetiracetam · Epilepsy.

Enrollment
23rd of 60
130 · median 94
Started
2006
with 4 others
Phase 3
28 of 60
2 open now
Registered
14th of 60
by date
Lead sponsor
23 of 60
UCB Pharma

Among the 60 studies testing levetiracetam in Epilepsy, this one is the 23rd largest by enrollment, is one of 5 that started in 2006, is one of 28 in phase 3, and was the 14th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

4 of the 60 studies testing levetiracetam in Epilepsy are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About levetiracetam

Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing levetiracetam in Epilepsy, or all of them as a file.
02

Study summary

For ethical reasons to give opportunity for adult subjects (≥16 or 18 years) suffering from newly diagnosed epilepsy who completed the therapeutic confirmatory, open-label trial N01175 (NCT00175903) conducted with levetiracetam in monotherapy and who benefited from the treatment, to receive treatment with levetiracetam until the monotherapy indication for levetiracetam is granted in Europe.

To continue to assess safety of levetiracetam as per adverse event reporting and observation of weight changes.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • NEWLY DIAGNOSED EPILEPSY
  • LEVETIRACETAM
  • KEPPRA
  • N01175 (NCT00175903)
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male/female adult subjects (≥ 16 or 18 years)
  • Diagnosis of epilepsy (all types of seizures may be included)
  • Subjects who completed N01175 (NCT00175903) trial and benefited from levetiracetam monotherapy

Other inclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

  • Subjects withdrawn from N01175 (NCT00175903) trial for any reason
  • Subjects who received treatment other than levetiracetam in N01175 (NCT00175903) trial
  • Subject requiring add-on antiepileptic treatment
  • Subjects from countries where levetiracetam is authorized for use as monotherapy in epilepsy treatment
  • Sexually active woman with who is not using a medically accepted method
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
130 participants (actual)

Study arms

  • Experimental
    Levetiracetam (LEV)

    Drug: Levetiracetam

Interventions

  • 500 mg oral tablets,1000 - 3000 mg/day, twice a day (BID), duration of the study

06

What researchers measure

Primary outcomes

  1. Assessment of Safety of Levetiracetam as Per Adverse Event (AE) Reporting in Open-label Therapy Phase

    Summarization for occurrence of adverse events like number of subjects with any adverse events or drug related adverse events is provided (see categories).

    Time frame: during open-label therapy phase of 18 months

Secondary outcomes

  1. Change From Baseline in Body Weight to Withdrawal or End of Study After 18 Months

    Time frame: Start of open-label therapy (Baseline) to withdrawal or end of study after 18 months

07

Results

Posted Nov 13, 2009

Participant flow

Participants Flow describes all subjects treated at least once during open-label monotherapy with Levetiracetam.

Participant flow — Overall Study
MilestoneLevetiracetam Open- Label Treatment
Started130
Completed115
Not completed15

Outcome measures

PrimaryAssessment of Safety of Levetiracetam as Per Adverse Event (AE) Reporting in Open-label Therapy Phase

Summarization for occurrence of adverse events like number of subjects with any adverse events or drug related adverse events is provided (see categories).

Time frame:
during open-label therapy phase of 18 months
Reported as:
Number · participants
Assessment of Safety of Levetiracetam as Per Adverse Event (AE) Reporting in Open-label Therapy Phase
participantsLevetiracetam Open- Label Treatment
Subjects with at least one AE40
Subjects with AEs leading to dose change8
Subjects with AEs leading to trial discontinuation1
Subjects with drug-related AEs16
Subjects with AEs of severe intensity4
Subjects with serious AEs6
Subjects with study drug-related serious AEs0
Number of deaths0
SecondaryChange From Baseline in Body Weight to Withdrawal or End of Study After 18 Months
Time frame:
Start of open-label therapy (Baseline) to withdrawal or end of study after 18 months
Reported as:
Mean · kg
Change From Baseline in Body Weight to Withdrawal or End of Study After 18 Months
kgLevetiracetam Open- Label Treatment
Change From Baseline in Body Weight to Withdrawal or End of Study After 18 Months0.71 ± 3.16

Adverse events

Collected over Open-label treatment over 18 months. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Levetiracetam Open- Label Treatment—6/130 (4.6%)10/130 (7.7%)
Most frequent serious events
Most frequent serious events
EventLevetiracetam Open- Label Treatment
Acute coronary syndromeCardiac disorders1/130
Hepatic cirrhosisHepatobiliary disorders1/130
Skin lacerationInjury, poisoning and procedural complications1/130
Grand mal convulsionNervous system disorders1/130
AlcoholismPsychiatric disorders1/130
TonsillitisInfections and infestations1/130
Foot fractureInjury, poisoning and procedural complications1/130
Most frequent other events
Most frequent other events
EventLevetiracetam Open- Label Treatment
Weight increasedInvestigations7/130
Weight decreasedInvestigations3/130

Baseline characteristics

Age, Continuous
Age, Continuous(years)Levetiracetam Open- Label Treatment
Mean40.68 ± 18.35
Sex: Female, Male
Sex: Female, Male(Participants)Levetiracetam Open- Label Treatment
Female58
Male72
Region of Enrollment
Region of Enrollment(participants)Levetiracetam Open- Label Treatment
France18
Finland9
Poland32
Belgium25
Bulgaria31
Switzerland15
08

Study locations

35 sites
  • Brugge, Belgium
  • Edegem, Belgium
  • Gent, Belgium
  • Haine St Paul, Belgium
  • Jette, Belgium
  • Kortrijk, Belgium
  • Leuven, Belgium
  • Oostende, Belgium
  • Sofia, Bulgaria
  • Varna, Bulgaria
  • Hus (helsinki), Finland
  • Kuopio, Finland
  • Tampere, Finland
  • Blaye, France
  • Bordeaux, France
  • Brest, France
  • Carcassonne, France
  • Cherbourg, France
  • Lille, France
  • Lyon Cedex, France
  • Nancy, France
  • Rennes, France
  • Saint Brieuc, France
  • Saint Quentin, France
  • TOULOUSE Cedex 04, France
  • Valenciennes, France
  • Czestochowa, Poland
  • Krakow, Poland
  • Olstyn, Poland
  • Poznan, Poland
  • Warszawa, Poland
  • Biel, Switzerland
  • Lausanne, Switzerland
  • St Gallen, Switzerland
  • Zurich, Switzerland
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2009, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2006
First posted
Feb 14, 2006
Start
Jun 2006
Primary completionActual
Apr 2008
CompletionActual
Apr 2008
Results first posted
Nov 13, 2009
Last update
May 18, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00291655
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Feb 14, 2006
Start date
Jun 2006
Primary completion
Apr 2008
Completion
Apr 2008
Results posted
Nov 13, 2009
Last update
May 18, 2015

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion